雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

An Update on Therapeutic Management in Autoimmune Encephalitis Satoshi Kamei 1 1Center for Neuro-infections, Ageo Central General Hospital Keyword: 自己免疫性脳炎 , NMDA受容体脳炎 , 症候性てんかん , 治療指針 , 難治例 , autoimmune encephalitis , NMDA receptor encephalitis , symptomatic epilepsy , therapeutic management , refractory patient pp.479-484
Published Date 2023/5/1
DOI https://doi.org/10.11477/mf.1416202362
  • Abstract
  • Look Inside
  • Reference

Abstract

In the last 15 years, the continual discovery of newly identified forms of autoimmune encephalitis (AE) associated with antibodies to the cell surface or synaptic proteins has changed the paradigms for diagnosing and treating disorders. AE is one of the most common causes of noninfectious encephalitis. It can be triggered by tumors or, infections, or it may be cryptogenic. These disorders can occur in children or young adults with or without cancer who develop psychosis, catatonic or autistic features, memory problems, abnormal movements, or seizures. Here, we review the therapeutic management of AE. The importance of early recognition and diagnosis of AE is paramount to the ultimate goal of optimal immunotherapy. Although no specific data are available for all autoantibody-mediated encephalitis syndromes, the two most common forms of AE, which are NMDA receptor encephalitis and LGI-1 encephalitis, are clear exemplars where improved patient outcomes are associated with early immunotherapy. First-line treatments for AE include intravenous steroids and intravenous immunoglobulins, which can be combined in most severe cases. Rituximab and cyclophosphamide are administered as second-line agents in unresponsive cases. A minority of patients may remain refractory to treatment, thus representing a major clinical challenge. In these cases, the treatment strategies are controversial, and no guidelines exist. Treatments proposed for refractory AE include (1) cytokine-based drugs such as tocilizumab, and (2) plasma cell-depleting agents such as bortezomib.


Copyright © 2023, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有